LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated in ...

AMD had something of a mixed year, but more was happening with its CPUs compared to the firm’s graphics cards.

Taiwan’s science ministry warned on Friday that funding for areas such as semiconductors, AI and aerospace could be reduced ...